[Hydroxy 9-methyl 2-ellipticinium acetate (NSC 264-137). Toxicologic study and therapeutic effect in 100 cancers (author's transl)].
A new derivative of ellipticine, hydroxy-9-methyl-2-ellipticinium acetate, was found to be a useful anti-tumor drug in advanced cancers which could not be treated any longer successfully by any other procedure. In our series of 100 patients, the best results were obtained with bone metastases from breast carcinomas and with anaplastic thyroid carcinomas. Most patients usually received a weekly perfusion of 80 mg/m2. The main characteristic of this drug is its lack of hematologic, and hepatic toxicity. No renal trouble was observed during the first year, but 2 deaths from renal insufficiency occured during the 18th and 15th month of treatment. The most frequent side effect consists of digestive troubles (nausea, vomiting) which rarely compelled to stop the treatment (4 times in 100 patients).
D000470:Alkaloids / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy*; D004361:Drug Tolerance; D004611:Ellipticines / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D013964:Thyroid Neoplasms / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D000470:Alkaloids; D004611:Ellipticines
L'acétate d'hydroxy 9-méthyl 2-ellipticinium (NSC 264-137). Etude toxicologique et thérapeutique chez 100 cancéreux.